Peritonitis Clinical Trial
— DIVERTI 2Official title:
Role of Protective Stoma After Primary Anastomosis for Generalized Peritonitis Due to Perforated Diverticulitis: a Prospective Multicenter Randomized Trial
NCT number | NCT04604730 |
Other study ID # | 2019/409/HP |
Secondary ID | |
Status | Recruiting |
Phase | N/A |
First received | |
Last updated | |
Start date | June 11, 2021 |
Est. completion date | June 1, 2026 |
This study is designed to be a multicentre, prospective, comparative, randomised trial, evaluating the efficacy of two surgical strategies for the treatment of generalised peritonitis due to perforated diverticulitis. Results will be analysed according to an intention to treat principle (after selection and patient consent). Immediately before surgery, the patient will be randomly assigned to sigmoidectomy with primary anastomosis or to sigmoidectomy with primary anastomosis and diverting stoma. Sigmoidectomy will be performed through a midline laparotomy or laparoscopically according to the standard technique. In the control arm, a protective stoma will be performed at the end of surgery. A stoma reversal operation will be performed at least 3 months after the first operation and after performing a cologram by water soluble contrast between 4 and 8 weeks to check for the absence of fistula or stenosis at the level of the anastomosis. Stoma reversal will be performed with a trephine incision. Post-stoma closure follow-ups will be planned and all morbidity/mortality will be recorded. All patients will be examined at 6, 12, and 24 weeks after the initial surgery, in the surgical department where they were operated; a final study visit will be carried out 12 months (evaluation of primary endpoint) after surgery. The parameters explored at medical examinations will be: • Occurrence of complications • Quality of life assessment
Status | Recruiting |
Enrollment | 204 |
Est. completion date | June 1, 2026 |
Est. primary completion date | June 1, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: 1. Age = 18 years 2. Patients operated for purulent or fecal peritonitis (Hinchey grade III and IV) secondary to perforated diverticulitis of the left colon and treated by resection with primary anastomosis 3. Person informed and having signed his consent. If the patient is unable to sign his consent, the consent will be signed by his representative ((1) the trusted person, or failing that, (2) a family member, or (3) a relative of the person concerned) (Article L1122-1-1 of the CSP). In this case, consent to continue the study will subsequently be requested from the patient. --> In addition, due to the vital urgency represented by hospitalisation in intensive care for purulent or fecal peritonitis, inclusion without prior collection of the consent of the patient or his/her representative is possible in the case where the patient is not capable of giving consent and his/her representative is not present at the time of inclusion (Article L1122-1-3 of the CSP). In this case, the patient or his/her representative will be informed as soon as possible and his/her written consent will be requested for the possible continuation of this research and the use of the data concerning him/her. 4. Patient able to comply with the study protocol, in the investigator's judgment 5. Patient affiliated with, or beneficiary of a social security (health insurance) category Non-inclusion Criteria: 1. Physical states that prevent patient participation (e.g. septic shock or multivisceral failure) 2. Steroid treatment > 20 mg daily 3. Prior pelvic irradiation 4. Immunocompromised status 5. Known progressive cancer 6. American Society of Anesthesiologists grade IV 7. Peritonitis secondary to perforated diverticulitis of the right colon 8. Patient is a pregnant (positive blood pregnancy test) or breastfeeding (lactating) woman or intending to become pregnant during the study 9. Person deprived of liberty by administrative or judicial decision or placed under judicial protection (guardianship or supervision) 10. Simultaneous participation in another interventional research Exclusion Criteria: 1. Failure to obtain the consent of the patient or the patient's representative |
Country | Name | City | State |
---|---|---|---|
France | CHU Amiens | Amiens | |
France | CH Beauvais | Beauvais | |
France | CHU Besançon | Besançon | |
France | APHP Avicenne | Bobigny | |
France | CHU Brest | Brest | |
France | CHU Caen | Caen | |
France | CHU Clermont Ferrand | Clermont-Ferrand | |
France | APHP Henri Mondor | Créteil | |
France | CHU Grenoble | Grenoble | |
France | CHU Limoges | Limoges | |
France | CHU Lyon | Lyon | |
France | APHM Hôpital Nord | Marseille | |
France | APHM La Timone | Marseille | |
France | CHU Nancy | Nancy | |
France | CHU Nantes | Nantes | |
France | CHU Nimes | Nîmes | |
France | APHP St Antoine | Paris | |
France | CHU Rouen | Rouen | |
France | CHU Tours | Tours |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Rouen |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Comparison of overall morbidity between "with protective stoma" and "without protective stoma" | Overall morbidity graded 0 to 5 according to the Clavien-Dindo classification All complications occurring during hospitalization will be collected. Late complications occurring after hospitalization will be collected during follow-up. | 12 months posteoperatively | |
Secondary | Comparison of the rate of death between "with protective stoma" and "without protective stoma" | rate of death at 3 months after surgery (%) | 3 months postoperatively | |
Secondary | Comparison of the rate of reinterventions between "with protective stoma" and "without protective stoma" | the rate of reinterventions after the surgery (%) | 12 months postoperatively | |
Secondary | Comparison of the rate of incisional surgical site infection (SSI) between "with protective stoma" and "without protective stoma" | the rate of incisional SSI (%) | 12 months postoperatively | |
Secondary | Comparison of the rate of organ/space SSI between "with protective stoma" and "without protective stoma" | the rate of organ/space SSI (%) | 12 months postoperatively | |
Secondary | Comparison of the rate of wound disruptions between "with protective stoma" and "without protective stoma" | the rate of wound disruptions (%) | 12 months postoperatively | |
Secondary | Comparison of the rate of anastomotic leaks between "with protective stoma" and "without protective stoma" | the rate of anastomotic leaks (%) | 12 months postoperatively | |
Secondary | Comparison of operating time between "with protective stoma" and "without protective stoma" | time of surgery (hours) | surgery | |
Secondary | Comparison of length of postoperative hospital stay between "with protective stoma" and "without protective stoma" | Length of postoperative hospital stay (days) | 6 months postoperatively | |
Secondary | Comparison of Intensive Care Unit (ICU) length of stay between "with protective stoma" and "without protective stoma" | ICU length of stay (days) | 6 months postoperatively | |
Secondary | Comparison of the number of patients alive without stoma between "with protective stoma" and "without protective stoma" | Number of patients alive without stoma at 12 months after initial surgery | 12 months after initial surgery | |
Secondary | Comparison of the quality of life between "with protective stoma" and "without protective stoma" | Quality of life evaluated using the Short Form Health Survey (SF-36) questionnaire at baseline, 6, 12, 26 and 52 weeks after primary surgery Score from 1 to 30 | 6, 12, 26 and 52 weeks after primary surgery | |
Secondary | Comparison of the quality of life between "with protective stoma" and "without protective stoma" with "EuroQol-5 Dimensions" questionnaire | Quality of life evaluated using EuroQol-5 Dimensions (EQ-5D) questionnaire at baseline, 6, 12, 26 and 52 weeks after primary surgery Each dimension has three levels of response: no problems (coded 1), some problems (coded 2) and major problems (coded 3), which defines 243 possible health states (35), to which can be added unconscious and dead states, for a total of 245 states. Thus, the health states range from "11111" (no problems on all dimensions) to "33333": major problems on all dimensions + visual analog scale from 0 to 100, 0 being the worst and 100 the best | 6, 12, 26 and 52 weeks after primary surgery | |
Secondary | Comparison of the quality of life between "with protective stoma" and "without protective stoma" with the Gastrintestinal Quality of Life Index questionnaire | Quality of life evaluated using Ethe Gastrintestinal Quality of Life Index questionnaire at baseline, 6, 12, 26 and 52 weeks after primary surgery Score from 0 to 144, the higher the score, the better the quality of life | 6, 12, 26 and 52 weeks after primary surgery | |
Secondary | Comparison of the cost utility between "with protective stoma" and "without protective stoma" | Quality-Adjusted Life Year (QALY) derived from the EQ5D-5L questionnaire | 12 months after primary surgery |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04070196 -
Point-of-care Test for Diagnosis of Peritonitis in Peritoneal Dialysis Patients
|
N/A | |
Completed |
NCT00657566 -
SIS Multicenter Study of Duration of Antibiotics for Intraabdominal Infection
|
Phase 3 | |
Recruiting |
NCT00131196 -
Functional Genomic Influences on Disease Progression and Outcome in Sepsis
|
N/A | |
Completed |
NCT00195351 -
Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection
|
Phase 4 | |
Completed |
NCT04182217 -
Descriptive and Correlational Study of Peritonitis in Haiti.
|
||
Recruiting |
NCT03310606 -
Serum and Peritoneal Concentration in Antibiotics During the Surgical Management of Peritonitis
|
N/A | |
Completed |
NCT01222663 -
Effects of Hemoperfusion With a Polymyxin B Membrane in Peritonitis With Septic Shock
|
Phase 3 | |
Completed |
NCT00230971 -
Study Comparing Tigecycline Versus Ceftriaxone Sodium Plus Metronidazole in Complicated Intra-abdominal Infection (cIAI)
|
Phase 4 | |
Recruiting |
NCT03790176 -
ZAVI APD ELF Protocol v2.2
|
Phase 1 | |
Completed |
NCT03668197 -
Children Peritonitis Ecology at CHU de Rennes - (IIAPEDIA)
|
||
Recruiting |
NCT01837342 -
Multicenter Study Comparing Morbidity and Quality of Life Associated in the Treatment by Surgical Resection and the Conservative Treatment, After Favorable Evolution of Purulent Peritonitis That Originates From Diverticulitis Treated by Mini-invasive Surgery
|
N/A | |
Completed |
NCT00497744 -
A Pharmacokinetic Study of Cefepime After Administration Into Dialysate in Patients With Continuous Ambulatory Peritoneal Dialysis (CAPD) Peritonitis
|
N/A | |
Recruiting |
NCT03334006 -
Prospective, Randomized Trial of Personalized Medicine With Pentaglobin® After Surgical Infectious Source Control in Patients With Peritonitis (PEPPER Trial).
|
Phase 2 | |
Terminated |
NCT03403751 -
Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury
|
Phase 3 | |
Withdrawn |
NCT00463762 -
Cefoperazone/Sulbactam In The Treatment Of Serious Intra-Abdominal And Hepatobiliary Infections.
|
Phase 4 | |
Active, not recruiting |
NCT02755610 -
Check List to Improve Patient Self-care and Product Defect Report in Continuous Ambulatory Peritoneal Dialysis
|
N/A | |
Not yet recruiting |
NCT05308849 -
Peritoneal Diffusion and Efficacy of Antibiotic Therapy in Pediatric Peritonitis
|
N/A | |
Completed |
NCT02726932 -
Intra-abdominal View and Inflammatory Markers in Secondary Peritonitis - Correlation to Recovery
|
||
Recruiting |
NCT05050253 -
Lavage With Super-Oxidized Solution for Secondary Peritonitis
|
N/A | |
Completed |
NCT02926846 -
IV Antibiotics With Lavage for Severe PD Peritonitis
|
Phase 4 |